Kornimate/medical-research-clean huggingface dataset:
caffeine and cocaine

Conditions: Cocaine Dependence

Summary: this study is being done to find out if medicines that affect a neurotransmitter (chemical messenger) in the brain called adenosine improve behavioral problems that are related to drug abuse. another purpose of the study is to find out how genes related to adenosine change how people respond to these medicines. more information about how these medicines change behaviors may be helpful to come up with new treatments for drug abuse.

specific aims: aim 1. to characterize the behavioral and subjective effects of acute caffeine administration in cocaine-dependent subjects, using laboratory measures of impulse control, drug discrimination (with d-amphetamine as the training dose), and subjective effects. hypotheses related to aim 1: 1. subjects will show decreases in impulsivity (delay to reward and response inhibition) after acute oral doses of caffeine compared to placebo. 2. subjects will show some stimulant-like subjective effects following acute oral doses of caffeine, but not the euphoric effects that would predict abuse potential.

Eligibility criteria:
inclusion criteria: * subjects who currently meet dsm-iv criteria for cocaine dependence and healthy controls * at least one cocaine positive urine during screening. * current regular consumption of caffeine. * female subjects: a negative pregnancy test. exclusion criteria: * current or past dsm-iv axis i disorder other than substance abuse/ dependence * any significant non-psychiatric medical illness requiring ongoing medical treatment or which would preclude treatment with d-amphetamine or caffeine * substance dependence other than cocaine within the last 3 months. * positive breath alcohol. * positive urine drug screen for drugs other than cocaine or thc at the time of behavioral testing * for female subjects: known pregnancy or a positive pregnancy test or current breast feeding. * diagnosis of adult attention deficit disorder as determined by: a) meeting dsm-iv criteria for childhood adhd, b) currently has impairing adhd symptoms, c) adhd symptoms can not have remitted at any period since childhood. * hiv positive. * i.q. below 70.

Keywords: substance abuse cocaine caffeine impulsivity
efficacy and safety of 14-day concomitant therapy for refractory helicobacter pylori infection

Conditions: Helicobacter Pylori Infection

Summary: the purpose of this study is to evaluate efficacy of a 14-day concomitant therapy for the third-line treatment of helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates.

helicobacter pylori infects half of the world's population. h.pylori eradication is an effective approach to reduce the risk of developing gastric cancer. however, eradication rates of first-line therapy decreased over years due to the rapidly increasing antibiotic resistance of h. pylori worldwide. an ideal rescue therapeutic regimen to cure refractory h.pylori infection is currently warranted. few published paper evaluated the efficacy of 14-day furazolidone containing concomitant therapy in the third line treatment. this study aims to propose a new concomitant therapy for the patients with three or more treatment failure, and then evaluates whether adverse effects are tolerable. .

Eligibility criteria:
inclusion criteria: * patients aged 18-70 years were recruited for this study if they had failed at least three rounds of anti- h. pylori therapies. exclusion criteria: * patients treated with h2-receptor antagonist, ppi, vonoprazan, bismuth and antibiotics in the previous 4 weeks * patients with gastorectomy, acute gi bleeding and advanced gastric cancer, * history of allergy to any of the drugs used in the study, * severe concomitant cardiovascular, respiratory, or endocrine diseases, clinically significant renal or hepatic disease, hematologic disorders and any other clinically significant medical condition that could increase risk, * currently pregnant or lactating, * severe neurologic or psychiatric disorders, * alcohol abuse or drug addiction, * patients with compliance lower than 90% in any previous treatment, * inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.

Keywords: concomitant therapy,rescue treatment
laparoscopic "da vinci" robot assisted abdominal wall hernia repair

Conditions: Abdominal Wall Hernia

Summary: the aim of this study is to prove the superiority of the robotic assistance in laparoscopic repair of abdominal wall hernias . in this monocentric randomized controlled trial, the use of the da vinci robot might reduce the post-operative pain of the patient resulting in a 40% reduction of morphine consumption.

laparoscopic robot assisted abdominal wall hernia repair : a prospective randomized trial: the main judgement criterion is post operative pain reflected by morphine consumption during the first 48 hours. secondary criteria are morbidity, quality of life, duration of surgery, conversion rate, complications, the the length of stay and hospital costs. in this single centre study, inclusion criteria are age above 18, no previous repair of the hernia with a mesh and a diameter of the parietal defect of less than 10 cm. contraindications are chronic use of pain drugs of level ii or above and renal insufficiency (clearance \<30ml/min). the robotic repair was described in a previous paper of our group and will be compared to our classical laparoscopic repair technique, and in both cases with the use of the same prosthetic mesh. a total of 70 patients to be included in an 18 months period was calculated to prove a 40% reduction in morphine consumption during the postoperative 48h (α=5% and β=10%). the total duration of the study is 30 months (12 months of follow-up for each patient).

Eligibility criteria:
inclusion criteria: * over 18 years * with indication of hernia repair * a collar with a diameter of less than 10cm * no antecedent of hernia treatment with poses plate * agreeing coelioscopy * agreeing to participate the clinical study, having sign an informed consent * agreeing a regular monitor exclusion criteria: * taking analgesic tier 2 or 3 * against indication to anesthetics or coelioscopy * creatinine clearance less than 30 ml/min * pregnant woman and protected persons * no affiliation to social security * unable to understand the information form

Keywords: treatment of abdominal ruptured digestive system disease coelioscopy assistance robotics medical device da vinci robot pain patient morphine consumption comparative randomized study patient over 18 years with ruptured abdominal with an indication of treatment of ruptured
glucagon-like peptide-1 receptor pet/ct in glp-1r related disease

Conditions: GLP1-R-related Disease; Tumor; Insulinoma; Positron Emission Tomography

Summary: to evaluate the potential usefulness of 68ga/18f-exendin 4 positron emission tomography/computed tomography (pet/ct) for the diagnosis of primary and metastatic lesions in various glp-1r-related disease patients.

subjects with various glp1-r-related disease patients underwent 68ga/18f-exendin 4 pet/ct either for an initial assessment or for recurrence detection. lesions uptake was quantified by the maximum standard uptake value (suvmax). the sensitivity, specificity, positive predictive value (ppv), negative predictive value (npv) and accuracy of 68ga/18f-exendin 4 pet/ct were calculated.

Eligibility criteria:
inclusion criteria: - (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include mri, ct, tumor markers and pathology report); (iii) patients who had scheduled exendin 4 pet/ct scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the clinical research ethics committee. exclusion criteria: - (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Keywords: pet/ct glp1-r
study of acuvue® advance® plus contact lenses.

Conditions: Myopia

Summary: the purpose of this study is to compare acuvue® advance® plus contact lenses made prior to process qualification (prepq) against the acuvue® advance® plus lenses made after the process qualification (postpq).


Eligibility criteria:
inclusion criteria: * the subject must be at least 18 years of age and no more than 39 years of age. * the subject is a current spherical soft contact lens wearer and willing to wear the study lenses on a daily wear basis for the duration of the study (minimum of 6 hours per day). * the subject's optimal vertexed spherical equivalent distance correction must be between -1.00 and - 5.00d. * any cylinder power must be ≤ -0.75d. * the subject must have visual acuity best correctable to 20/25+3 or better for each eye. * the subject must read and sign the statement of informed consent. * the subject must appear able and willing to adhere to the instructions set forth in this clinical protocol. exclusion criteria: * ocular or systemic allergies or disease which might interfere with contact lens wear. * systemic disease or use of medication which might interfere with contact lens wear. * clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear. * clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear. * any ocular infection. * any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear. * pregnancy or lactation. * diabetes. * infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease (e.g. hiv). * habitual contact lens type is toric, multifocal, or is worn as extended wear.
low dose ketamine study on opioid tolerance and hyperalgesia

Conditions: Idiopathic Scoliosis; Spondylolisthesis

Summary: the purpose of this study is to: 1. establish whether ketamine can decrease opioid consumption and modulate the onset of opioid tolerance and prevent opioid-induced hyperalgesia in pediatric subjects, ages 10 years to 18 years, undergoing posterior spinal fusion and instrumentation.


Eligibility criteria:
inclusion criteria: 1. the subject is 10 to 18 years of age 2. the subject's american society of anesthesiologists physical status is asa 1, 2 or 3 (see appendix i) 3. the subject is scheduled for elective posterior spinal fusion and instrumentation. 4. the subject's parent/legally authorized guardian has given written informed consent to participate exclusion criteria: 1. the subject has a history or a family (parent or sibling) history of malignant hyperthermia 2. the subject is pregnant or nursing. 3. the subject has known significant renal disorders determined by medical history, physical examination or laboratory tests 4. the subject has a known or suspected allergy to morphine, remifentanil or ketamine 5. the subject is an asa classification of 4 or greater (see appendix i) 6. the subject is scheduled for a surgical sub-procedure (i.e. anterior spinal fusion) 7. the subject is unable to self-administer morphine using patient-controlled analgesia (pca) pump 8. the subject had a recent opioid exposure (within 1 month of surgery) 9. the subject is obese (body mass index \>30kg/m2) 10. the subject is planned for elective postoperative ventilation 11. the subject has a known ocular disease not permitting pupillometric examination 12. the subject has used any investigation products in the past 30 days

Keywords: opioid tolerance hyperalgesia scoliosis pupillometry
discovering new genetic markers in adults and children who may be at risk for hereditary forms of cancer

Conditions: Cancer

Summary: this study is being done to attempt to identify genetic mutations or other gene-based variations in adults and children who have cancer, or are likely to develop an inherited form of cancer, and potentially reduce their risk for cancer or treat the cancer earlier.


Eligibility criteria:
inclusion criteria: * individuals who have undergone clinical and/or research genetic evaluation, found to have or not have a germline genetic variant (pathogenic, likely pathogenic, variant of uncertain/unknown significance, likely benign). * individuals with or without a personal history of malignant or pre-malignant lesions who demonstrate: a) clinical findings suggestive of a genetic cancer susceptibility syndrome including very early age at onset, multiple primary malignancies, or other features; and/or b) family histories suggestive of a genetic cancer susceptibility syndrome, or c) other features suggesting inherited etiology of malignancy as determined by the pi. * family members of the above participants. both children (with parental consent as age appropriate) and adults are eligible to participation. * individuals may or may not be enrolled msk patients; probands may be referred to (or self-referred to) the study and may be enrolled at discretion of the pi and if able to provide informed consent. * biospecimens derived from deceased family members may be used for research in this study if consent if provided by the executor of the estate of that individual. exclusion criteria: * patients will be excluded from this study if he/she has physical, cognitive or psychiatric conditions that interfere with ability to give meaningful informed consent.

Keywords: genetic evaluation germline genetic variant genetic cancer memorial sloan kettering cancer center 19-133
tolerance and acceptability evaluation of aymes amsterdam

Conditions: Malnutrition

Summary: to evaluate tolerance and acceptability of 'amsterdam' in patients requiring supplementary oral nutritional support compared with currently available alternatives.

to evaluate tolerance and acceptability of 'amsterdam' in patients requiring supplementary oral nutritional support compared with currently available alternatives, measuring outcomes of gi effects, compliance, product preference, convenience etc. to obtain data to support an acbs submissions for 'amsterdam' (to allow for prescription in the community at nhs expense).

Eligibility criteria:
inclusion criteria: * male and female participants. * ≥ 18 years of age. * participants of the intended target group (e.g. must score ≥ 1) with an anticipated period of nutritional support ≥ 7 days. * patient is able and willing to provide written informed consent. exclusion criteria: * participants with medical or dietary contraindication to any feed ingredients. * participants requiring sole enteral tube feeding or parenteral nutrition. * participants with significant renal (requiring dialysis) or hepatic impairment (e.g. hepatitis.) * participants with dysphagia requiring levels 1, 2, 3 or 4 thickened fluids. * participants with uncontrolled inflammatory bowel disease or previous bowel resection with ongoing gastrointestinal symptoms. * participants for whom the investigator has concerns regarding the ability or willingness of the patient and or carer to comply with protocol requirements. * participation in any other studies involving investigational or marketed products concomitantly or within 2 weeks prior to entry into the study.
extension study to evaluate the safety and tolerability of nbi-921352 when used with anti-seizure medications in adults with focal onset seizures

Conditions: Focal Onset Seizure; Focal Onset Epilepsy

Summary: this phase 2, prospective, interventional, active extension study was designed to evaluate the long-term safety and tolerability of nbi-921352 as adjunctive therapy in adult participants with focal onset seizures who completed 11 weeks of treatment in randomized, double-blind, placebo-controlled study nbi-921352-fos2021. eligible participants may enroll directly following the completion of the week 11 study visit of study nbi-921352-fos2021 or after a gap following completion of that study.


Eligibility criteria:
key inclusion criteria: * provided informed consent. * completed 11 weeks of treatment in study nbi-921352-fos2021. * stable treatment with at least 1 but not more than 4 antiseizure medicines. key exclusion criteria: * have developed any other disorder for which the treatment takes priority over the treatment of focal onset seizure or is likely to interfere with study treatment or impair treatment compliance.

Keywords: epilepsy focal seizure sodium channel voltage-gated alpha subunit nav1.6 inhibitor antiseizure medicine asm antiepileptic drug aed partial seizure partial onset epilepsy
relationship between anterior tibial subluxation and the prognosis of anterior cruciate ligament reconstruction.

Conditions: Anterior Cruciate Ligament Injuries

Summary: to identify the improvement of anterior tibial subluxation (ats) and the relationship between ats and patient reported outcome on pre- and postoperative anterior cruciate ligament-injured mri images.

the value of preoperative anterior tibial subluxation (ats) was used for the division of anterior cruciate ligament-injured patients in 2 groups. ats was measured on pre- and postoperative mri images. patients were followed up 2 years after anterior cruciate ligament reconstruction, and patient reported outcomes (i.e. lysholm score, etc.) were collected for further analysis.

Eligibility criteria:
inclusion criteria: (1) diagnosed anterior cruciate ligament injuries; (2) available preoperative mri scans at our hospital. - exclusion criteria: patients were excluded in the case of under 18 years of age, bilateral anterior cruciate ligament injuries, concomitant posterior cruciate ligament injuries, concomitant collateral ligament injuries, and no access to the preoperative mri scan at our hospital. -

Keywords: anterior tibial subluxation
the effect of healthwear on short-term weight loss

Conditions: Weight Loss; Obesity

Summary: the purpose of this study is to examine the effect of a computer tracking system and energy expenditure device on weight loss in adults.


Eligibility criteria:
inclusion criteria: 1. 18-55 years of age. 2. body mass index (bmi) between 25.0-39.9 kg/m2. 3. access to a computer, internet access, and will demonstrate proficiency with using the internet and web-based software programs. potential participants will be asked to provide the type of computer they have, the name of their internet service provider, and will have to demonstrate their ability to search the internet during their screening visit. exclusion criteria: 1. report losing \>5% of current body weight in the previous 6 months. 2. report participating in a research project involving weight loss or physical activity in the previous 6 months. 3. for women, report being pregnant during the previous 6 months, or planning on becoming pregnant over the following 3 months of the intervention. (pregnancy during initial screening will be based on self-report and will be included on the detailed medical history that is completed by subjects. in addition, this will also be obtained as part of the signed medical clearance from the individual's personal physician.) 4. currently being treated for any medical condition that could impact body weight (i.e., diabetes mellitus, cancer, etc.). 5. history of myocardial infarction, or a history of undergoing heart surgery such as bypass or angioplasty. 6. taking medication that would affect heart rate or blood pressure responses to exercise (e.g., beta blockers). 7. taking medication that could affect metabolism and/or contribute to a change in body weight (e.g., synthroid). 8. being treated by a therapist for psychological issues or problems, taking pyschotropic medications, or receiving treatment with psychotropic medications within the previous 6 months. 9. no exclusion criteria shall be based on race, ethnicity, or gender.
screening for coronary artery disease using primary evaluation with coronary cta in aviation medicine (suspect)

Conditions: Coronary Artery Disease (CAD); Coronary Artery Calcification; Occupational Diseases; Aviator's; Disease

Summary: suspect is a prospective, single-center, cohort study of 250 military aircrew at the center for man in aviation, royal netherlands air force. all asymptomatic aircrew (≥40 years) are asked to undergo a coronary ct scan on a voluntary basis, following the exercise electrocardiograms performed at their routine aeromedical examination. coronary artery calcium score (cacs) and ccta findings are reported.


Eligibility criteria:
inclusion criteria: * military aircrew of the royal netherlands air force * ≥ 40 years old * required to undergo cardiac screening (per military aviation regulations) exclusion criteria: * typical angina * prior myocardial infarction * prior revascularization therapy (i.e. percutaneous coronary intervention (pci) and/or coronary artery bypass grafting (cabg)) * left ventricular ejection fraction \<35% * does not comprehend study requirements, and/or is unwilling or unable to comply to study procedures * ct-related contra-indications * allergic to iodine contrast. * renal insufficiency (gfr \<60 ml/min/1.73m2, calculated with the modification of diet in renal disease (mdrd) calculator: http://nephron.org/mdrd_gfr_si. * severe claustrophobia. * uncontrolled irregular heart rhythm or tachycardia unresponsive to beta blockade * pregnancy
a phase 1 ascending and parallel group trial to establish the safety, tolerability and pharmacokinetics profile of volociximab (alpha 5 beta 1 integrin antagonist) in subjects with neovascular age- related macular degeneration

Conditions: Age-related Macular Degeneration

Summary: the objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of volociximab intravitreous injection in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (amd).


Eligibility criteria:
inclusion criteria: * subfoveal choroidal neovascularization (cnv) due to amd (i.e., predominantly classic, minimally classic or occult no classic) as documented by fluorescein angiogram. exclusion criteria: * any prior treatment for amd or any intravitreal treatment for any indication in the study eye prior to the screening visit, except oral supplements of vitamins and minerals. * previous or concomitant therapy with intravitreous corticosteroids. * any of the following underlying diseases including: * diabetic retinopathy * history or evidence of severe cardiac disease (e.g., nyha functional class iii or iv - see appendix 19.6), history or clinical evidence of unstable angina, acute coronary syndrome, myocardial infarction or revascularization within last 6 months, ventricular tachyarrythmias requiring ongoing treatment. * history or evidence of clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation. * clinically significant impaired renal (serum creatinine \>2.5 mg/dl or s/p renal transplant or receiving dialysis) or hepatic function. patients with results outside these ranges may be enrolled in consultation with ophthotech. * stroke (within 12 months of trial entry). * any major surgical procedure within one month of trial entry. * previous therapeutic radiation in the region of the study eye. * any treatment with an investigational agent in the past 60 days for any condition. * women who are pregnant or nursing. * known serious allergies to the fluorescein dye used in angiography, to the components of the ranibizumab formulation, or to the components of the volociximab formulation.

Keywords: amd